iRadimed (IRMD)
(Delayed Data from NSDQ)
$44.40 USD
-1.75 (-3.79%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $44.26 -0.14 (-0.32%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IRMD 44.40 -1.75(-3.79%)
Will IRMD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IRMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IRMD
IRadimed (IRMD) Surpasses Q2 Earnings and Revenue Estimates
Acadia Healthcare (ACHC) Opens Facility to Serve California
IRMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
UnitedHealth (UNH) Unit Awarded a Medicaid Contract by AHCCCS
Centene's (CNC) Ambetter Enhances Offerings With Broward Health
Centene (CNC) Wins Contract From Arizona's Medicaid Agency
Other News for IRMD
IRADIMED CORPORATION (IRMD) Q2 2024 Earnings Call Transcript
iRadimed price target lowered by $5 at Roth MKM, here's why
Iradimed (IRMD) Gets a Buy from Roth MKM
IRADIMED CORPORATION Announces Second Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share
iRadimed Non-GAAP EPS of $0.42 beats by $0.06, revenue of $17.93M beats by $0.28M